CVS Health's stock has taken significant
hits recently, as the company battles both increasing
Medicare costs and a profit outlook slash that has investors worried. A class action lawsuit for allegedly
inflating insulin prices has also been a cause for concern. As a result, the
company's 2024 forecast has been cut thrice. Despite these challenges, CVS Health continues to pursue its long-term growth strategy through various means including the
expansion of health services on a national scale and the
establishment of Workforce Innovation Talent Centers. However, experts deem the company's stock as
undervalued and see it as a potential
buying opportunity. Reinforcing this sentiment, CVS Health announced a
quarterly dividend of $0.67 indicating some level of steady cashflow. The serenity of their situation is further threatened by CVS having a
potential loss of up to 10% of its Medicare members next year. Notably, CVS expanded into Phoenix with a more than
$3M investment to boost health outcomes, a move that shows the company's push to remain a leading health services provider notwithstanding the existent tumults.
Cvs Health Corporation CVS News Analytics from Tue, 05 Dec 2023 08:00:00 GMT to Sun, 22 Sep 2024 11:45:00 GMT -
